---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-060281"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2024-07-10T23:59:59+00:00"
generated_at: "2026-05-31T22:10:09.595728+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Longeveron receives FDA RMAT designation for Lomecel-B in mild Alzheimer's disease

## Summary
- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for Lomecel-B for mild Alzheimer's disease.
- Lomecel-B is the first cellular therapeutic candidate to receive RMAT designation for Alzheimer's disease.
- CLEAR MIND Phase 2a trial met primary safety and secondary efficacy endpoints; full results at AAIC on July 28, 2024.
- This is the fourth special FDA designation for Lomecel-B; HLHS program holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations.
- RMAT designation enables intensive FDA guidance and potential expedited review and accelerated approval pathways.

## SEC filing metadata
- accession: 0001213900-24-060281
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2024-07-10T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390024060281/0001213900-24-060281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390024060281/ea0209181-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-060281
- JSON: https://secwatch.observer/filing/0001213900-24-060281.json
- Plain text: https://secwatch.observer/filing/0001213900-24-060281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.